Sugi Predict

Sugi Predict / Compounds / SCHEMBL3371558

SCHEMBL3371558

SCHEMBL3371558

CCOC(=O)[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]1CO

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.50
▸ PDE4B Q07343 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPT P10636 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NAMPT P43490 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ TACR1 P25103 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ PDE4A P27815 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20670636 0.92 NR1H2 (0.46) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL30835940 0.92 NR1H2 (0.46) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL1052491 0.88 NR1H2 (0.50) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL2930654 0.88 NR1H2 (0.50) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL2930651 0.88 NR1H2 (0.50) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL1013664 0.86 NR1H2 (0.52) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL14805510 0.85 NR1H2 (0.41) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL24555863 0.84 NR1H2 (0.47) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL21564451 0.84 NR1H2 (0.47) NR1H2PDE4BALDH1A1MEN1KMT2A
SCHEMBL19385247 0.84 NR1H2 (0.47) NR1H2PDE4BALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863477-B1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2010-11-03 — — EP disclosed
US-7807709-B2 Organic compounds NOVARTIS AG (CH) 2010-10-05 — — US disclosed
US-7807709-B2 Organic compounds NOVARTIS AG (CH) 2010-10-05 — — US disclosed
US-7807709-B2 Organic compounds NOVARTIS AG (CH) 2010-10-05 — — US disclosed
US-20080194549-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-14 — — US disclosed
US-20080194549-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-14 — — US disclosed
US-20080194549-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-14 — — US disclosed
EP-1863477-A1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION Novartis AG (CH) 2007-12-12 — — EP disclosed
WO-2006100036-A1 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2006-09-28 — — WO disclosed
WO-2006100036-A1 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2006-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194549-A1 Organic Compounds REN, ACE, OTC NR1H2 2620/4885PDE4B 1099/4885ALDH1A1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.